2020 SALES: €427.5M (UP 8.0% AS REPORTED, UP 10.9% AT CONSTANT EXCHANGE RATE) ESSENTIALS SALES: €220.6M (UP 15.7% AS REPORTED, UP 17.3% AT CONSTANT EXCHANGE RATE)
Vetoquinol CEO Matthieu Frechin said: “2020 was an exceptional year on a number of counts. Above all, it is important to pay tribute to our teams, whose hard work and exemplary dedication allowed us to manage the impact of the health crisis. Year on year, we achieved double-digit sales growth at constant exchange rates, driven by our Essentials products. This momentum accounts for additional sales of €43 million (at constant exchange rates). We also completed a major acquisition in the form of the Drontal® and Profender® product ranges, entailing three structural effects for Vetoquinol: a scale effect, a product mix effect in the Essentials range and potential extensions, the first of which has been confirmed in January 2021 for the Australian market. We are optimistic for our business outlook in 2021, while being vigilant in relation to the global sanitary situation.”
- Public releases
Vetoquinol has been listed on the Euronext Paris stock market since November 16th.
Composition of the bodies of Corporate Management and Governance
Financial information and key figures: annual, half-year and by sector key figures